Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)

Angde Biotech Pharmaceutical

Status and phase: Unknown; Phase 2

Conditions: Acute Pulmonary Embolism

Treatments: Drug: Recombinant human tissue-type plasminogen activator derivative; Drug: Recombinant human tissue-type plasminogen activator

Study type: Interventional

Funder types: Industry

Identifiers

NCT04110275

CRAD-RTL-203

Details and patient eligibility

About

The purpose of this trial is to compare the efficacy and safety of Recombinant Human Tissue-Type Plasminogen Activator Derivative(rPA) and Recombinant Tissue-Type Plasminogen Activator(rt-PA) for the treatment of acute pulmonary embolism.

This trial includes two stages, the first stage is to study the dosage of administration of the test drug(rPA), the second is to compare the efficacy and safety of rPA and rt-PA. Both of the two stages are randomized, open and parallel controlled.

Full description

This trial is a multicenter, randomized, open and parallel controlled project designed for patients with acute pulmonary embolism requiring thrombolysis after anticoagulant therapy in high-risk and middle-high risk populations.

For the first stage: Subjects who are qualified for the screening criteria according to the inclusion and exclusion criteria will be randomly assigned to low-dose test drugs, high-dose test drugs or reference drugs for thrombolytic therapy at a ratio of 1:1:1.

For the second stage: Subjects who are qualified for the screening criteria according to the inclusion and exclusion criteria will be randomly assigned to rPA(test group)or rt-PA(control group) for thrombolytic therapy at a ratio of 1:1.

Enrollment: 174 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with high-risk acute pulmonary embolism: the main manifestations are shock and hypotension.Systemic systolic blood pressure <90 millimetre of mercury (mmHg) (1mmHg=0.133kPa), or a decrease from the base value ≥40 millimetre of mercury for more than 15min.
• Patients with moderate to high-risk acute pulmonary embolism who have worsened anticoagulant therapy require thrombolytic therapy:

(Patients with moderate to high-risk acute pulmonary embolism: Right ventricular dysfunction (RVD) and elevated cardiac biomarkers coexist.)

1. RVD diagnostic criteria: imaging evidence including echocardiography or CT:1) Ultrasound examination is consistent with the following performance: 1. right ventricular dilatation (right ventricular end-diastolic diameter / left ventricular end-diastolic diameter > 1.0 or 0.9); 2. right ventricular free wall movement amplitude decreased; 3. tricuspid regurgitation speed increased; 4. tricuspid annulus systolic displacement decreased (<17mm); 2) Computed Tomographic Pulmonary Angiography examination meets the following conditions: right ventricular dilatation (right ventricular end-diastolic diameter / left ventricular end-diastolic diameter > 1.0 or 0.9) found at the four-chamber heart level;
2. Cardiac biological markers including N terminal pro B type natriuretic peptide (NT-proBNP/BNP) and troponin elevation;

Diagnostic criteria for worsening after anticoagulant therapy in patients with moderate to high risk acute pulmonary embolism:

Hemodynamic deterioration (defined as meeting at least one of the following conditions: 1. requires cardiopulmonary resuscitation; 2. systemic systolic blood pressure <90 mmHg (1 mmHg = 0.133 kPa), or a decrease in basal value ≥ 40 mmHg for more than 15 min, or with terminal Low organ perfusion (limb cold or urine volume <30 ml/hr, or mental confusion); 3. need to infuse a booster drug (except dopamine <5 μg/kg/min) to maintain adequate tissue perfusion and systolic blood pressure > 90 mmHg ;

• The time from onset to the time of thrombolysis is ≤ 14 days;
• Male patients must agree to take effective contraceptive measures during treatment and at least 28 days after the end of the trial, and do not donate sperm during this period; women of childbearing age must be negative within the first 72 hours of randomization, and agree to adopt effective contraceptive measures during treatment and at least 28 days afterwards the last treatment.
• Voluntary signing of written informed consent form.

Exclusion criteria

• a history of hemorrhagic stroke or unexplained stroke;
• Ischemic stroke or transient ischemic attack within 3 months;
• Central nervous system damage or tumor;
• Surgery and trauma of the brain or spine within 2 months;
• Active internal bleeding within 1 month (such as gastrointestinal bleeding, hemoptysis, blood in the stool, etc.);
• High risk of bleeding: evidence or history of bleeding disorders, bleeding tendency, bleeding constitution or coagulopathy;
• oral anticoagulant (can be randomized after a certain period of time, such as oral rivaroxaban can be randomized after 1 day of elution, oral warfarin can be performed at International Normalized Ratio <2.0 random);
• 1 week after pregnancy or delivery;
• vascular puncture of the site that cannot be oppressed;
• Cardiopulmonary resuscitation within 10 days;
• Hypertension that is difficult to control (systolic blood pressure > 180 mmHg and / or diastolic blood pressure ≥ 110 mmHg);
• Liver function is grade C of Child-Pugh ;
• Infective endocarditis;
• History of aneurysms or arteriovenous malformations, or suspected aortic dissection;
• Cardiac thrombosis;
• Diabetes with hemorrhagic retinopathy or other hemorrhagic eye diseases;
• Laboratory inspection:Platelets (PLT) <90×109/L;Alanine aminotransferase (ALT) > 2.5 × ULN, aspartate aminotransferase (AST) > 2.5 ×Upper Limit of Normal (ULN);Endogenous creatinine clearance (Ccr) ≤ 50ml/min (calculated according to the Cockcroft-Gault formula);Alkaline phosphatase (ALP) > 2.0 × ULN;
• Severe cardiac insufficiency occurred in the past 6 months, New York Heart Association Heart Function Rating (NYHA classification) ≥ III;
• Participate in other clinical trials within 1 month prior to enrollment;
• Known or suspected hypersensitivity to plasminogen activator, or allergic to contrast agents, or drugs administered during the trial;
• People with mental disorders;
• Accompanied by other serious diseases that may prevent them from entering or affecting their survival, such as cancer or AIDS;
• Any disease or condition that is not suitable for intravenous thrombolysis;
• Other diseases or conditions that the investigator believes are not suitable for the trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

174 participants in 3 patient groups

low dose group

Experimental group

Description:

Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more. A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection.

Treatment:

Drug: Recombinant human tissue-type plasminogen activator derivative

high dose group

Experimental group

Description:

Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes. A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection.

Treatment:

Drug: Recombinant human tissue-type plasminogen activator derivative

comparative group

Active Comparator group

Description:

Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.

Treatment:

Drug: Recombinant human tissue-type plasminogen activator